Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. Th…
Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm,…
EQT Infrastructure VI, through its indirectly owned subsidiary Otello BidCo AB, announces a recommen…
Vinge has advised Tobii AB (publ) in connection with a fully guaranteed rights issue of ordinary sha…
Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrate…
Vinge has advised CTEK AB (publ) on a fully guaranteed rights issue, which will provide CTEK with is…
Vinge has advised Acrinova AB (publ) (“Acrinova” or the “Company”) in connection with the Company’s…
Vinge has advised A3P Biomedical in connection with an issue of shares amounting to SEK 400 million…
Vinge has advised EQT in connection with the combination with Baring Private Equity Asia, a leading…
Vinge advises Cell Impact AB (publ) in connection with a fully guaranteed rights issue which will pr…
Vinge has advised CTEK AB (publ) (“CTEK” or the “Company”) in connection with its listing on Nasdaq…
Vinge advises Sleep Cycle AB (publ) (“Sleep Cycle” or the “Company”) in connection with the listing…
Vinge is advising Acrinova AB (publ) in connection with a rights issue which will provide Acrinova w…
Vinge advises Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with its public offer…
Vinge has advised Gränges AB (publ) in connection with a fully guaranteed rights issue of approximat…
Vinge has advised Offentliga Hus i Norden AB (publ) (“Offentliga Hus”) in connection with its listin…
